Form 4: Aptevo Therapeutics Director Converts Restricted Stock Units to Common Stock

Aptevo Therapeutics Inc. Director Grady Grant III acquired one share of common stock through the conversion of a restricted stock unit on July 17, 2025.

Summary

• Grady Grant III, a Director of Aptevo Therapeutics Inc., acquired 1 share of the company's common stock.
• This acquisition resulted from the conversion of a Restricted Stock Unit (RSU) on July 17, 2025.
• The RSU was originally granted on July 17, 2024, for 925 pre-split units, which became 1 post-split unit following a stock split.
• The RSU vested in full one year from its grant date, leading to the conversion.

Sentiment

Score: 6

Explanation: The conversion of a Restricted Stock Unit into common stock for a director is a routine equity compensation event. While it increases insider ownership, the minimal number of shares involved limits its broader market significance.

Positives

• Director Grady Grant III increased direct ownership of Aptevo Therapeutics Inc. common stock by 1 share, indicating continued alignment with shareholder interests.

Future Outlook

No forward-looking statements or guidance are provided in this insider transaction report.

Industry Context

This filing is a routine disclosure of an insider equity transaction, specific to Aptevo Therapeutics Inc., and does not provide broader industry context or trends.

Related Party Transactions

• The transaction involves the conversion of Restricted Stock Units (RSUs) granted to Director Grady Grant III, which is a form of equity compensation and a standard related-party transaction.

Stakeholder Impact

• Shareholders: The transaction results in a minor increase in direct ownership by a company director, which can be viewed as a positive alignment of interests, though the impact is negligible due to the small number of shares.

Key Dates

Recommendation

Keywords

Aptevo Therapeutics, APVO, Form 4, Insider Trading, Restricted Stock Units, RSU Conversion, Equity Compensation, Director Ownership